Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.
Naggie S, Marks KM, Hughes M, Fierer DS, Macbrayne C, Kim A, Hollabaugh K, Roa J, Symonds B, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Chung R; AIDS Clinical Trials Group (ACTG) A5327 Study Team. Naggie S, et al. Clin Infect Dis. 2017 Apr 15;64(8):1035-1042. doi: 10.1093/cid/cix025. Clin Infect Dis. 2017. PMID: 28329053 Free PMC article. Clinical Trial.
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.
Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, Urban TJ, Shianna KV, Muir AJ, Fried MW, Afdhal NH, Goldstein DB, McHutchison JG. Thompson AJ, et al. Among authors: naggie s. Gastroenterology. 2010 Oct;139(4):1181-9. doi: 10.1053/j.gastro.2010.06.016. Epub 2010 Jun 12. Gastroenterology. 2010. PMID: 20547162 Free PMC article.
Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.
Medrano J, Neukam K, Rallón N, Rivero A, Resino S, Naggie S, Caruz A, Calvino A, Macías J, Benito JM, Sánchez-Piedra C, Vispo E, Barreiro P, McHutchison J, Pineda JA, Soriano V. Medrano J, et al. Among authors: naggie s. Clin Infect Dis. 2010 Nov 15;51(10):1209-16. doi: 10.1086/656811. Clin Infect Dis. 2010. PMID: 20964522
Hepatitis C pharmacogenetics: state of the art in 2010.
Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Shianna KV, Tanaka Y, Thomas DL, Booth DR, Goldstein DB; Pharmacogenetics and Hepatitis C Meeting Participants. Afdhal NH, et al. Hepatology. 2011 Jan;53(1):336-45. doi: 10.1002/hep.24052. Hepatology. 2011. PMID: 21254181 Review.
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L, Petruzzellis D, Romano M, Sogari F, Facciorusso D, Goldstein DB, McHutchison JG, Mangia A. Thompson AJ, et al. Among authors: naggie s. Hepatology. 2011 Feb;53(2):389-95. doi: 10.1002/hep.24068. Epub 2011 Jan 10. Hepatology. 2011. PMID: 21274861 Free PMC article. Clinical Trial.
150 results